Pegylated liposomal doxorubicin in elderly patients with metastatic breast cancer

References

• Dellapasqua S, Colleoni M, Castiglione M, Goldhirsch A. New criteria for selecting elderly patients for breast cancer adjuvant treatment studies. Oncologist12(8), 952–959 (2007).
   Google Scholar
• Carreca I, Balducci L, Extermann M. Cancer in the older person. Cancer Treat. Rev.31(5), 380–402 (2005).
   PubMed Web of Science ®Google Scholar
• Diab SG, Elledge RM, Clark GM. Tumor characteristics and clinical outcome of elderly women with breast cancer. J. Natl Cancer Inst.92(7), 550–555 (2000).
   PubMed Web of Science ®Google Scholar
• Crivellari D, Aapro M, Leonard R et al. Breast cancer in the elderly. J. Clin. Oncol.25(14), 1882–1890 (2007).
   PubMed Web of Science ®Google Scholar
• Puglisi F, Cardoso F, Lebrun F, Piccart M. First-line treatment of metastatic breast cancer: available evidence and current recommendations. Am. J. Cancer5(2), 99–110 (2006).
   Google Scholar
• Repetto L, Fratino L, Audisio RA et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J. Clin. Oncol.20(2), 494–502 (2002).
   PubMed Web of Science ®Google Scholar
• Min LC, Elliott MN, Wenger NS, Saliba D. Higher vulnerable elders survey scores predict death and functional decline in vulnerable older people. J. Am. Geriatr. Soc.54(3), 507–511 (2006).
   PubMed Web of Science ®Google Scholar
• Balducci L. Management of cancer in the elderly. Oncology (Williston Park NY)20(2) 135–143 (2006).
   PubMed Web of Science ®Google Scholar
• Muss HB, Berry DA, Cirrincione C et al. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. J. Clin. Oncol.25(24), 3699–3704 (2007).
   PubMed Web of Science ®Google Scholar
• Jones RL, Swanton C, Ewer MS. Anthracycline cardiotoxicity. Expert Opin. Drug Saf.5(6), 791–809 (2006).
   PubMed Web of Science ®Google Scholar
• Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer97(11), 2869–2879 (2003).
   PubMed Web of Science ®Google Scholar
• Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J. Clin. Oncol.25(25), 3808–3815 (2007).
   PubMed Web of Science ®Google Scholar
• Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin. Pharmacokinet.42(5), 419–436 (2003).
   PubMed Web of Science ®Google Scholar
• Gabizon A, Price DC, Huberty J, Bresalier RS, Papahadjopoulos D. Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: biodistribution and imaging studies. Cancer Res.50(19), 6371–6378 (1990).
   PubMed Web of Science ®Google Scholar
• Gabizon A, Catane R, Uziely B et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res.54(4), 987–992 (1994).
   PubMed Web of Science ®Google Scholar
• Amantea MA, Forrest A, Northfelt DW, Mamelok R. Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi’s sarcoma. Clin. Pharmacol. Ther.61(3), 301–311 (1997).
   PubMed Web of Science ®Google Scholar
• Symon Z, Peyser A, Tzemach D et al. Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes. Cancer86(1), 727–728 (1999).
   Google Scholar
• Durbecq V, Paesmans M, Cardoso F et al. Topoisomerase-II a expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Mol. Cancer Ther.3(10), 1207–1214 (2004).
   PubMed Web of Science ®Google Scholar
• Uziely B, Jeffers S, Isacson R et al. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary Phase I studies. J. Clin. Oncol.13(7), 1777–1785 (1995).
   PubMed Web of Science ®Google Scholar
• Ranson MR, Carmichael J, O’Byrne K, Stewart S, Smith D, Howell A. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter Phase II trial. J. Clin. Oncol.15(10), 3185–3191 (1997).
   PubMed Web of Science ®Google Scholar
• Mlineritsch B, Mayer P, Rass C et al. Phase II study of single-agent pegylated liposomal doxorubicin HCl (PLD) in metastatic breast cancer after first-line treatment failure. Onkologie27(5), 441–446 (2004).
   Google Scholar
• Al-Batran SE, Bischoff J, von Minckwitz G et al. The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre Phase II trial. Br. J. Cancer94(11), 1615–1620 (2006).
   Google Scholar
• Lyass O, Uziely B, Ben-Yosef R et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer89(5), 1037–1047 (2000).
   PubMed Web of Science ®Google Scholar
• Caraglia M, Addeo R, Costanzo R et al. Phase II study of temozolomide plus pegylated liposomal doxorubicin in the treatment of brain metastases from solid tumours. Cancer Chemother. Pharmacol.57, 343–349 (2006).
   Google Scholar
• O’Brien ME, Wigler N, Inbar M et al. Reduced cardiotoxicity and comparable efficacy in a Phase III trial of pegylated liposomal doxorubicin HCl (Caelyx/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann. Oncol.15(3), 440–449 (2004).
   PubMed Web of Science ®Google Scholar
• Keller AM, Mennel RG, Georgoulias VA et al. Randomized Phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J. Clin. Oncol.22(19), 3893–3901 (2004).
   PubMed Web of Science ®Google Scholar
• Batist G, Ramakrishnan G, Rao CS et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J. Clin. Oncol.19(5),1444–1454 (2001).
   PubMed Web of Science ®Google Scholar
• Harris L, Batist G, Belt R et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer94(1), 253–256 (2002).
   Google Scholar
• Chan S, Davidson N, Juozaityte E et al. Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer. Ann. Oncol.15(10), 1527–1534 (2004).
   PubMed Web of Science ®Google Scholar
• Hamilton A, Biganzoli L, Coleman R et al. EORTC 10968: a Phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. European Organization for Research and Treatment of Cancer. Ann. Oncol.13(6), 910–918 (2002).
   PubMed Web of Science ®Google Scholar
• Coleman RE, Biganzoli L, Canney P et al. A randomised Phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993). Eur. J. Cancer42(70), 882–887 (2006).
   PubMed Web of Science ®Google Scholar
• Biganzoli L, Coleman R, Minisini A et al. A joined analysis of two European Organization for the Research and Treatment of Cancer (EORTC) studies to evaluate the role of pegylated liposomal doxorubicin (Caelyx) in the treatment of elderly patients with metastatic breast cancer. Crit. Rev. Oncol. Hematol.61(1), 848–849 (2007).
   Google Scholar
• Addeo R, Faiola V, Guarrasi R et al. Liposomal pegylated doxorubicin plus vinorelbine combination as first-line chemotherapy for metastatic breast cancer in elderly women >/=65 years of age. Cancer Chemother. Pharmacol. (2007).(Epub ahead of print).
   Google Scholar
• Lorusso V, Di Stefano A, Carone V, Fagotti A, Pisconti S, Scambia G. Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia (“hand-foot” syndrome). Ann. Oncol.18(7), 1159–1164 (2007).
   PubMed Web of Science ®Google Scholar
• O’Shaughnessy JA. Pegylated liposomal doxorubicin in the treatment of breast cancer. Clin. Breast Cancer4(5), 318–328 (2003).
   PubMedGoogle Scholar
• Molpus KL, Anderson LB, Craig CL, Puleo JG. The effect of regional cooling on toxicity associated with intravenous infusion of pegylated liposomal doxorubicin in recurrent ovarian carcinoma. Gynecol. Oncol.93(2), 513–516 (2004).
   PubMed Web of Science ®Google Scholar
• Honecker F, Mayer F, Hilger R et al. Reduction of skin toxicity of pegylated liposomal doxorubicin (PLD) by concomitant administration of dexamethasone and pyridoxine (PYR) in patients (PTS) with anthracycline-sensitive malignancies: a Phase I/II trial. J. Cancer Res. Clin. Oncol.128, 848 (2002).
   Google Scholar
• Al-Batran SE, Meerpohl HG, von Minckwitz G et al. Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter Phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer. Oncology70, 141–146 (2006).
   Google Scholar
• Overmoyer B, Silverman P, Holder LW, Tripathy D, Henderson IC. Pegylated liposomal doxorubicin and cyclophosphamide as first-line therapy for patients with metastatic or recurrent breast cancer. Clin. Breast Cancer6(2), 150–157 (2005).
   Google Scholar
• Alexopoulos A, Karamouzis MV, Stavrinides H et al. Phase II study of pegylated liposomal doxorubicin (Caelyx) and docetaxel as first-line treatment in metastatic breast cancer. Ann. Oncol.15(6), 891–895 (2004).
   PubMed Web of Science ®Google Scholar
• Vorobiof DA, Rapoport BL, Chasen MR et al. First line therapy with paclitaxel (Taxol) and pegylated liposomal doxorubicin (Caelyx) in patients with metastatic breast cancer: a multicentre Phase II study. Breast13(3), 219–226 (2004).
   PubMed Web of Science ®Google Scholar
• Schwonzen M, Kurbacher CM, Mallmann P. Liposomal doxorubicin and weekly paclitaxel in the treatment of metastatic breast cancer. Anticancer Drugs.11(9), 681–685 (2000).
   PubMed Web of Science ®Google Scholar
• Bourgeois H, Ferru A, Lortholary A et al. Phase I–II study of pegylated liposomal doxorubicin combined with weekly paclitaxel as first-line treatment in patients with metastatic breast cancer. Am. J. Clin. Oncol.29(3), 267–275 (2006).
   Google Scholar
• Sparano JA, Malik U, Rajdev L, Sarta C, Hopkins U, Wolff AC. Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer. J. Clin. Oncol.19(12), 3117–3125 (2001).
   PubMed Web of Science ®Google Scholar
• Alexopoulos A, Karamouzis MV, Stavrinides H et al. Phase II study of pegylated liposomal doxorubicin (Caelyx) and docetaxel as first-line treatment in metastatic breast cancer. Ann. Oncol.15(6), 891–895 (2004).
   PubMed Web of Science ®Google Scholar
• Morabito A, Gattuso D, Stani SC et al. Safety and activity of the combination of pegylated liposomal doxorubicin and weekly docetaxel in advanced breast cancer. Breast Cancer Res. Treat.86(3), 249–257 (2004).
   Google Scholar
• Gebbia V, Mauceri G, Fallica G et al. Pegylated liposomal doxorubicin with vinorelbine in metastatic breast carcinoma. A Phase I–II clinical investigation. Oncology.63(1), 23–30 (2002).
   PubMedGoogle Scholar
• Martin M, Garcia-Donas J, Casado A et al. Phase II study of pegylated liposomal doxorubicin plus vinorelbine in breast cancer with previous anthracycline exposure. Clin. Breast Cancer5(5), 353–357 (2004).
   Google Scholar
• Chow LW, Yip AY, Lang BH. A Phase II trial of vinorelbine and pegylated liposomal doxorubicin in patients with pretreated metastatic breast cancer. Am. J. Clin. Oncol.30(2), 133–138 (2007).
   Google Scholar
• Ardavanis A, Mavroudis D, Kalbakis K et al. Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: a multicentre Phase II study. Cancer Chemother. Pharmacol.58(6), 742–748 (2006).
   PubMed Web of Science ®Google Scholar
• Rivera E, Valero V, Arun B et al. Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. J. Clin. Oncol.21(17), 3249–3254 (2003).
   PubMed Web of Science ®Google Scholar
• Fabi A, Ferretti G, Papaldo P et al. Pegylated liposomal doxorubicin in combination with gemcitabine: a Phase II study in anthracycline-naive and anthracycline pretreated metastatic breast cancer patients. Cancer Chemother. Pharmacol.57(5), 615–623 (2006).
   PubMedGoogle Scholar
• Ulrich-Pur H, Kornek GV, Haider K et al. Phase II trial of pegylated liposomal doxorubicin (Caelyx) plus gemcitabine in chemotherapeutically pretreated patients with advanced breast cancer. Acta Oncol.46(2), 208–213 (2007).
   PubMed Web of Science ®Google Scholar
• Chia S, Clemons M, Martin LA et al. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter Phase II trial. J. Clin. Oncol.24(18), 2773–2778 (2006).
   PubMed Web of Science ®Google Scholar